Healthcare / BiotechnologyKOSDAQ
$5520.00
-170.00 (-2.99%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $-43.6M · quality 44.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
29/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$48.7B
P/E
100.4x
↑EV/EBITDA
18.5x
↑ROE
0.9%
↑Gross Margin
22.5%
↓Debt/Equity
0.14
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-9.7%
FCF CAGR
—
FCF margin
5.5%
FCF / Net income
5.81x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $77.09B · net income $732.0M · FCF $4.25B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $77.09B | $77.09B | $75.41B | $89.57B | $104.71B |
| Net Income | $732.0M | $732.0M | $2.91B | $-117.5M | $10.16B |
| EBITDA | $2.70B | $2.70B | $5.25B | $1.84B | $17.33B |
| EPS | 55.00 | 55.00 | 327.41 | -13.37 | 777.63 |
| Gross Margin | 22.5% | 22.5% | 25.2% | 22.2% | 23.3% |
| Operating Margin | 0.9% | 0.9% | 1.3% | 2.8% | 8.8% |
| Net Margin | 0.9% | 0.9% | 3.9% | -0.1% | 9.7% |
| Balance Sheet | |||||
| Debt/Equity | 0.14 | 0.14 | 0.04 | 0.08 | 0.21 |
| Current Ratio | 2.23 | 2.23 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $4.25B | $4.25B | $-4.67B | $-43.6M | $-5.06B |
| Returns | |||||
| ROE | 0.9% | 0.9% | 3.5% | -0.1% | 12.0% |
| Valuation | |||||
| P/E | 100.36 | 100.36 | 21.73 | — | 13.67 |
| EV/EBITDA | 18.49 | 18.49 | 11.06 | 38.83 | 8.52 |
| P/B | 0.58 | 0.58 | 0.75 | 0.96 | 1.65 |
| Growth & Yield | |||||
| Revenue Growth | 2.2% | 2.2% | -15.8% | -14.5% | — |
| EPS Growth | -83.2% | -83.2% | 2549.6% | -101.7% | — |
| Dividend Yield | 1.8% | 1.8% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
107.3%
EPS terminal req.
$489.81
Spread vs growth
-190.5%
5Y implied EPS CAGR
60.9%
EPS terminal req.
$592.67
Spread vs growth
-144.1%
10Y implied EPS CAGR
33.0%
EPS terminal req.
$954.50
Spread vs growth
-116.2%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-15.1%
Start / end P/E
20.3x → 100.4x
EPS bridge
327.41 → 55.00
Residual
-328.2%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.